Table 3 The application of CRISPR/Cas9 in Rhabdomyosarcoma research
From: Applications of CRISPR/Cas9 in the research of malignant musculoskeletal tumors
Target Genes | Cell lines | CRISPR/Cas9 Applications | Effects | References |
|---|---|---|---|---|
Pax3,Foxo1 | Foxo1-inv+/+ myoblasts (mice)/primary myoblasts | induce chromosomal translocation | Pax3-Foxo1 chromosomal translocation ARSM model, no function research | [82] |
DMD | CCL-136 RD | knock out | Produce DMD deletion - immortalized muscle cell line | |
DYSF | TE671 | knock out | Myogenin↓,TSP-1 expression↑,membrane Repair ability ↓, | [85] |
Dozens genes | JR1,RD | knock out | Validates oncogenes and tumors suppressors defined by iExCN tool | [79] |
HDAC1–10 genes (class I and II HDAC genes) | 381 T, RD,SMS-CTR, Rh3,Rh5,Rh30 | knock out | cell growth↓, myogenic differentiation↑, xenografts tumor proliferation↓,differentiation↑, | [86] |
PAX3-FOXO1 | Dbt-MYCN / indP3F parental cellsa, recurrent tumour-derived cells. | knock out | Fail to form tumor in Dbt-MYCN/indP3F parental cells, form tumor in recurrent tumour-derived cells | [80] |
NRAS,HRAS | 381 T,SMS-CTR ERMS cells | knock out | Cell viability↓, apoptosis↑, G1 phase arrest, expression of key cell-cycle and DNA replication genes↓, median survival of mice↑,xenografts tumor growth↓, myogenic differentiation↑, tumor regression Perk expression↓ | [87] |